SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alliance Pharmaceutical
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: All Mtn Ski who wrote (299)8/16/1998 10:10:00 PM
From: 993racer  Read Replies (1) of 548
 
Another Liquvent's competitor down


CAMBRIDGE, Mass., Aug 13 (Reuters) - Transcend Therapeutics Inc. said Thursday that intravenous administration of
Procysteine was not effective for the treatment of acute respiratory distress syndrome (ARDS).

The company also said it can find no explanation for the higher all-cause mortality observed in the Procysteine group during
the Phase III trial.

The company said in May that it was discontinuing the Phase III trial to allow it to unblind the study and determine the safety
and efficacy of Procysteine.

''The company, along with its partner Boehringer Ingelheim, will make a determination on the future of Procysteine I.V. in the
near term,'' said Hector J. Gomez, M.D., Ph.D., president and chief executive officer of Transcend Therapeutics
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News